Carisma Therapeutics Files 8-K
Ticker: CARM · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1485003
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Carisma Therapeutics filed an 8-K on July 9th, reporting routine corporate events and financials.
AI Summary
Carisma Therapeutics Inc. filed an 8-K on July 9, 2024, reporting other events and financial statements. The company, formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc., is incorporated in Delaware and based in Philadelphia, PA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.
Risk Assessment
Risk Level: low — This filing appears to be a standard 8-K for reporting corporate events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Sesen Bio, Inc. (company) — Former company name
- Eleven Biotherapeutics, Inc. (company) — Former company name
- July 9, 2024 (date) — Date of earliest event reported
- 3675 Market Street, Suite 401 (location) — Principal business address
- Philadelphia, PA (location) — City and State of business address
- 19104 (location) — ZIP code of business address
FAQ
What is the primary purpose of this Form 8-K filing for Carisma Therapeutics Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 9, 2024.
When was the earliest event reported in this filing?
The earliest event reported was on July 9, 2024.
What were Carisma Therapeutics Inc.'s former company names?
Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc.
Where is Carisma Therapeutics Inc. located?
Carisma Therapeutics Inc.'s principal business address is 3675 Market Street, Suite 401, Philadelphia, PA 19104.
What is the SIC code for Carisma Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Carisma Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-07-09 07:30:18
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
Filing Documents
- tm2419051d1_8k.htm (8-K) — 28KB
- tm2419051d1_ex99-1.htm (EX-99.1) — 5KB
- tm2419051d1_ex99-1img001.jpg (GRAPHIC) — 332KB
- tm2419051d1_ex99-1img002.jpg (GRAPHIC) — 387KB
- tm2419051d1_ex99-1img003.jpg (GRAPHIC) — 379KB
- 0001104659-24-078451.txt ( ) — 1714KB
- carm-20240709.xsd (EX-101.SCH) — 3KB
- carm-20240709_lab.xml (EX-101.LAB) — 33KB
- carm-20240709_pre.xml (EX-101.PRE) — 22KB
- tm2419051d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On July 9, 2024, Carisma Therapeutics Inc. (the "Company") will announce new analysis related to the Company's Phase 1 clinical trial of CT-0508, a human epidermal growth factor receptor 2 ("HER2") targeted chimeric antigen receptor macrophage for the treatment of HER2 overexpressing cancers, during a presentation at the Stifel Virtual Cell Therapy Forum. An excerpt from the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company is providing the following analysis related to its Phase 1 clinical trial of CT-0508: The Company recently completed analysis of circulating tumor DNA ("ctDNA") from 13 patients enrolled in groups 1 and 2. Based on preliminary results assessed to date, the Company observed that 75% (n=6/8) of evaluable HER2 3+ patients experienced a ctDNA reduction, indicating direct tumor killing activity. Zero percent (n=0/5) of evaluable HER2 2+ patients experienced a ctDNA reduction. In the 6 patients that experienced a ctDNA reduction, the median decrease was 81% (range 33%-93% decrease in ctDNA 4-weeks post treatment with CT-0508). While the results from this early clinical trial data are both preliminary and limited, the Company believes that repeat dosing of its follow-on product, CT-0525, in patients with HER2 overexpressing cancers could prolong pharmacologic efficacy and response. Consistent with prior disclosure, enrollment of new patients in the Company's Phase 1 clinical trial of CT-0508 and its sub-study utilizing CT-0508 in combination with pembrolizumab was halted in April 2024 in connection with the implementation of the Company's revised operating plan. As of July 2024, all activities with respect to the patients enrolled in the Phase 1 clinical trial and sub-study have been completed. The Company only has preliminary results from the Phase 1 clinical trial and expects clinical data updates in the third quarter of 2024.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Excerpt from Company Presentation, dated July 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: July 9, 2024 Steven Kelly President and Chief Executive Officer